The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix； and b. an immunogen comprising an extracellular Her2/neu domain that is linked to a second peptidic alpha-helix coiled to the first alpha-helix； The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating Her2/neu positive tumor diseases.
